Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H9HT
|
||||
| Former ID |
DCL000656
|
||||
| Drug Name |
TAK-701
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Advanced malignancies [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [522563] | ||
| Company |
Takeda
|
||||
| Formula |
C18H16N6S2
|
||||
| Canonical SMILES |
[C-]#[N+]C(=C(N)SC1=CC=CC=C1N)C(=C(N)SC2=CC=CC=C2N)C#N
|
||||
| InChI |
1S/C18H16N6S2/c1-24-16(18(23)26-15-9-5-3-7-13(15)21)11(10-19)17(22)25-14-8-4-2-6-12(14)20/h2-9H,20-23H2/b17-11+,18-16-
|
||||
| InChIKey |
OSXOBXXOVNWNOP-UNEKJRSWSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Hepatocyte growth factor | Target Info | Modulator | ||
| Pathway Interaction Database | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | ||||
| Arf6 signaling events | |||||
| Signaling events mediated by TCPTP | |||||
| Direct p53 effectors | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Syndecan-1-mediated signaling events | |||||
| Stabilization and expansion of the E-cadherin adherens junction | |||||
| FGF signaling pathway | |||||
| References | |||||